ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / PHAR / forecast
CRVS (27) IVA (49) ALMS (19) OBX (34) ⌘ Pro Terminal →

Pharming Group N.V. ADS each representing 10 (PHAR) 12-Month Stock Forecast & Price Target Cone

$12.23 +0.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.22

Pharming Group N.V. ADS each representing 10 (PHAR) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →
ROARABLE D • SELL / AVOID Cap $856.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PHAR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PHAR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Pharming Group N.V. ADS each representing 10 (NASDAQ: PHAR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $12.23 (+0.82% 1D, market cap $856.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PHAR ranks #286 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PHAR compare to CRVS and IVA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHAR carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CRVS (Corvus Pharmaceuticals Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $860.6M) and IVA (Inventiva S.A. American Depository Shares) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, PHAR leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PHAR?
▼

For Pharming Group N.V. ADS each representing 10 (PHAR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #286 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $12.23 (-0.04%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (9)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.2% Base Target
$22 Bull$12 Base$9 Bear
📬 FREE PHAR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PHAR)Realized 20D OHLCV Swing Band: ±6.8%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY PHAR SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.6% FCF Margin ($24.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (68.3) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$9.61-5.2% Next Q
Q2 (-2Q)
46
Grade D$9.11+30.6% Next Q
Q3 (-1Q)
48
Grade D$11.90+2.8% Next Q
Current
51
Grade D$12.23-1.3% Hist 90D α
Trajectory: D (43) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PHAR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PHAR currently carries a cautious 51/100 (D) rating due to Macro Regime Fit (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.72) and Max Pain ($12.84) forces dealer call-delta covering toward $22.41.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PHAR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PHAR Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PHAR Position Size: $10,000

Shares at $12.23: 817.7 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $9.24
$7,555
$-2,445 (-24.4%)
12M Consensus BaseTarget $11.84
$9,681
$-319 (-3.2%)
12M Bull Case BreakoutTarget $22.41
$18,324
+$8,324 (+83.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 6
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$1274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$2169%B
JP MorganUS Large-Cap ResearchSELL$1158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PHAR)

  • ✓Walkthrough of PHAR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PHAR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.38%📐 HORIZONTAL RANGE
2026-11-02O $12.26H $12.26L $12.13C $12.23VOL 12.4K
RES: $17.89SUP: $9.02SMA50: $10.72SMA200: $13.75
$17.31$15.08$12.86$10.64$8.42RES $17.89SUP $9.02$12.232026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PHAR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PHAR Butterfly Map → + Track PHAR →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PHAR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PHAR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PHAR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PHAR)

Health Care Rank #286 of 1016 ⚔️ CRVS vs PHAR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PHAR vs. CRVS, IVA, ALMS, OBX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pharming Group N.V. ADS each representing 10 (PHAR) ranks #286 by composite RQD confidence (51/100, grade D) and #381 by equity capitalization ($856.7M). Within this direct 5-issuer industry benchmark cohort, PHAR leads on earnings valuation at N/A trailing P/E, while CRVS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PHAR currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PHAR ACTIVE
Pharming Group N.V. ADS each representing 10
D 51/100 — — — +0.82% $856.7M Benchmark Subject
CRVS
Corvus Pharmaceuticals Inc.
E 27/100 — — -35.0% -1.95% $860.6M /crvs-vs-phar →
IVA
Inventiva S.A. American Depository Shares
D 49/100 — — — -2.14% $881.3M /iva-vs-phar →
ALMS
Alumis Inc.
E 19/100 — — -35.0% -2.32% $891.8M /alms-vs-phar →
OBX
Obsidian Therapeutics Inc.
E 34/100 — — -35.0% +1.86% $896.9M /obx-vs-phar →

2. PHAR Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Pharming Group N.V. ADS each representing 10 (PHAR) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $856.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. PHAR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PHAR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Pharming Group N.V. ADS each representing 10 (NASDAQ: PHAR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $12.23 (+0.82% 1D, market cap $856.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PHAR ranks #286 in composite RQD confidence.

How does PHAR compare to CRVS and IVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PHAR carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CRVS (Corvus Pharmaceuticals Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $860.6M) and IVA (Inventiva S.A. American Depository Shares) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $881.3M). Among the 5-stock peer group, PHAR leads on earnings multiple (N/A) while CRVS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PHAR?

For Pharming Group N.V. ADS each representing 10 (PHAR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #286 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PHAR trading relative to its 50-day, 200-day, and 52-week technical levels?

PHAR last traded at $12.23 (+0.82% on volume of 14,053 shares), positioning the stock +14.09% above its 50-day simple moving average ($10.72) and -11.05% below its 200-day simple moving average ($13.75). Across its 52-week range of $9.11 to $21.34, PHAR sits at the 25.5% percentile with a 14-day RSI of 68.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.8% ($11.40 to $13.06).

PHAR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PHAR's 12-month stock price target?

Pharming Group N.V. ADS each representing 10 (PHAR) carries a 12-month consensus base price target of $11.84 (-3.2% from $12.23), with a bull-case target of $22.41 and a bear-case floor of $9.24.

Is PHAR stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates PHAR D (Sell — SELL) with an RQD Confidence score of 51/100.

Direct Sub-Reports: PHAR RQD Cockpit PHAR 12M Forecast PHAR Earnings & Move PHAR Dividends & DRIP PHAR Insiders & 13F PHAR Whale Options PHAR Profit Sankey PHAR News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PHAR — Pharming Group N.V. ADS each representing 10: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:14:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PHAR scores 51 out of 100, a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

  • Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. This is the weakest cash-generation signal in the framework and indicates that, on the source data, the business is not currently earning a return on invested capital or producing free cash flow relative to its price.
  • Whale 13F Flow: 9 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The sub-score is below midpoint, so the source data does not show strong institutional conviction.
  • Insider Conviction: 9 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The sub-score is below midpoint, so the source data does not show strong insider or congressional buying conviction.
  • Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector-sensitivity component. The sub-score is the lowest of the five, indicating limited framework-level alignment with the current macro regime.
  • Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, indicating a comparatively more stable balance sheet than the cash and flow signals.

For a prospective investor evaluating the stock today, the rating's implications are that the upside case rests less on current earnings or cash generation (both at 0% in the source data) and more on balance-sheet resilience and any future improvement in returns. The valuation tradeoff is that the source data provides no P/E, EPS, or EV/EBITDA figures, so the price of 12.13 cannot be benchmarked against earnings. The rating's distribution warning reflects the combination of weak cash-engine and flow signals. This is an educational reading of the framework, not personalized financial advice.

Business

Per the profile, Pharming Group N.V. ADS each representing 10 (PHAR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The source data does not describe its products, customers, or revenue model. Per the profile, its market capitalization is $0.9B. Beyond sector, industry, and exchange, the source data does not establish how the company makes money.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is listed as "NONE," with no butterfly links and no proprietary signals. Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations, but the source data does not map upstream or downstream dependencies, sector correlations, or second-order bottlenecks.

Open Questions

  • What products or revenue streams does the company generate, and from which customers?
  • What are the reported revenue, operating income, net income, and free cash flow across recent periods?
  • Why are ROIC and FCF yield reported at 0%, and is that a reporting gap or an economic reality?
  • What is the current consensus rating and price target, and how do they compare to the 12.13 price?
  • Which institutional, insider, or congressional holders are active, and what is the direction and size of their positions?

PHAR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pharming Group N.V. ADS each representing 10 (PHAR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PHAR Debate Forum (3) ↓
🟢 CATALYST Yahoo • 6d ago
Pharming Group Q3 Earnings Call Highlights

Pharming Group (NASDAQ:PHAR) reported third-quarter revenue growth of 21% to $117.6 million, supported by higher sales of its RUCONEST hereditary angioedema treatment and Joenja therapy for activated phosphoinositide 3-k

Read Full Source ↗
🟡 MARKET WIRE Benzinga • 6d ago
Pharming Q3 2026 Earnings Call Transcript

Pharming (NASDAQ:PHAR) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PHAR Bull vs. Bear Conversation Board — What's Your Call at $12.23?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PHAR 🐻 50% BEARISH CONVICTION
1. Pick Your Side on PHAR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $13.10 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PHAR (D • RQD 51/100) a Buy at $12.13?

Welcome to the PHAR (Pharming Group N.V. ADS each representing 10) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.70 (-20.0%)
Spot @ $12.13

Pump the brakes on PHAR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PHAR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Pharming Group N.V. ADS each representing 10 expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $14.31 (+18.0%)
Spot @ $12.13

PHAR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PHAR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $12.13 (52-wk range $9.11 - $21.34), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%